Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (611-620 of 642) with videos related to

Pageof 65
Sort By:
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
The New England Journal of Medicine|September 27, 2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
European Journal of Heart Failure|January 11, 2020
Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin TAlberto Aimo, James L Januzzi, Giuseppe Vergaro, et al.
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisMarco Valgimigli, Roxana Mehran, Anna Franzone, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
JACC. Cardiovascular Interventions|October 6, 2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass IndexVijay Kunadian, Usman Baber, Carlo A Pivato, et al.
JACC. Heart Failure|July 11, 2021
NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index CategoriesGiuseppe Vergaro, Francesco Gentile, Laura M G Meems, et al.
ESC Heart Failure|May 5, 2022
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failureGiuseppe Vergaro, Francesco Gentile, Alberto Aimo, et al.
Pageof 65

Showing results (611-620 of 642) with videos related to

Sort By:
Pageof 65
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
JACC. Cardiovascular Interventions|January 16, 2022
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT SubstudyMauro Chiarito, Usman Baber, Davide Cao, et al.
The New England Journal of Medicine|September 27, 2019
Ticagrelor with or without Aspirin in High-Risk Patients after PCIRoxana Mehran, Usman Baber, Samin K Sharma, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 9, 2021
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT studyGeorge Dangas, Usman Baber, Samin Sharma, et al.
European Journal of Heart Failure|January 11, 2020
Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin TAlberto Aimo, James L Januzzi, Giuseppe Vergaro, et al.
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisMarco Valgimigli, Roxana Mehran, Anna Franzone, et al.
European Heart Journal|October 21, 2020
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACSUsman Baber, George Dangas, Dominick Joseph Angiolillo, et al.
JACC. Cardiovascular Interventions|October 6, 2022
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass IndexVijay Kunadian, Usman Baber, Carlo A Pivato, et al.
JACC. Heart Failure|July 11, 2021
NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index CategoriesGiuseppe Vergaro, Francesco Gentile, Laura M G Meems, et al.
ESC Heart Failure|May 5, 2022
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failureGiuseppe Vergaro, Francesco Gentile, Alberto Aimo, et al.
Pageof 65